

The disclosures pursuant to Regulation 14 read with Part F of Schedule I of the SEBI ESOP Regulations as on March 31, 2026, are as follows:

On August 1, 2022, shareholders of Indiqube Spaces Limited (the "Company") approved the 'IndiQube- Employee Stock Option Plan 2022' ("ESOP 2022" / "ESOP Plan") via a special resolution at an Extraordinary General Meeting (EGM). The plan aims to attract, retain, and motivate key talent by rewarding high performance and driving overall corporate growth and profitability. To ensure regulatory compliance, the ESOP Plan was subsequently amended at the EGM held on November 16, 2024, to align with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("SEBI (SBEB & SE) Regulations").

S.No	Particulars	ESOP 2022	
1	The Board of Directors in their report shall disclose any material change in the scheme(s) and whether the scheme(s) is / are in compliance with the SEBI ESOP Regulations.	Following the listing of the Company's shares on July 30, 2025, the ESOP Plan required ratification by shareholders under Regulation 12(1) of the SEBI (SBEB & SE) Regulations before any fresh grants could be issued. Accordingly, the shareholders ratified the ESOP Plan on September 14, 2025, via a Postal Ballot. The updated ESOP Plan is available at: https://indiqube.com/investor/ .	
2	Relevant disclosures in terms of the accounting standards prescribed by the Central Government in terms of Section 133 of the Companies Act, 2013 (18 of 2013) including the 'Guidance note on accounting for employee share-based payments' issued in that regard from time to time.	The disclosures are provided in the note no. 34 of the financial statements for financial year ended March 31, 2026.	
3	Diluted EPS on issue of shares pursuant to all the schemes covered under the regulations shall be disclosed in accordance with 'Accounting Standard 20 - Earnings Per Share' issued by Central Government or any other relevant accounting standards as issued from time to time.	The disclosures are provided in the note no. 34 of the notes to of the Company for financial year ended March 31, 2026.	
4	A description of each Option that existed at any time during the year, including the general terms and conditions of each ESOS, including:		
	a	Date of shareholders' approval	August 01, 2022 (Initial) September 14, 2025 (Ratification)
	b	Total number of Options approved	40,61,200
	c	Vesting requirements	Vesting of Options would be a function of continued employment with the Company and achievement of performance criteria as specified by the Nomination & Remuneration Committee as communicated on Grant of Options. There shall be a minimum period of 1 (one) year between the Grant Date of the Options and the Vesting Date of the Options. The vesting may occur in one or more tranches, subject to the terms and conditions of vesting, as stipulated in the ESOP 2022.
	d	Exercise price or pricing formula	The Exercise Price per Option, subject to approval by the Nomination and Remuneration Committee, shall not be lesser than the face value of shares and not more than the Fair Market Value of the Share as on Grant Date of such options.
	e	Maximum term of Options(s) granted	The exercise period would commence from the date of vesting and will expire on the completion of 2 (two) years from the date of respective vesting or such period as may be determined by the committee from time to time. The maximum period of vesting shall not be later than maximum period of 4 (four years) from the date of grant.
	f	Source of shares (primary, secondary or combination)	Primary
	g	Variation in terms of Options (during the year)	Nil
	h	Method used to account for Options - Intrinsic or fair value	Fair Value
	i	In case the intrinsic value method has been used for valuation of the RSU(s), the difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognized if it had used the fair value of the RSU(s) shall be disclosed. The impact of this difference on profits and on EPS of the company shall also be disclosed.	NA

S.No	Particulars		ESOP 2022
5	Option movement during the year		
6	a	Particulars	Details
	b	Number of options outstanding at the beginning of the period	31,35,538
	c	Number of options granted during the year	-
	d	Number of options forfeited / lapsed during the year	37,017
	e	Number of options vested during the year	7,76,233
	f	Number of options exercised during the year	19,86,127
	g	Number of shares arising as a result of exercise of options	19,86,127
	h	Money realized by exercise of options (INR), if scheme is implemented directly by the company	19,86,127
	i	Loan repaid by the Trust during the year from exercise price received	Nil
	j	Number of options outstanding at the end of the year	11,12,394
	k	Number of options exercisable at the end of the year	69,490
7	Weighted-average exercise prices and weighted-average fair values of options shall be disclosed separately for options whose exercise price either equals or exceeds or is less than the market price of the stock.		Members may refer to note No. 34 of the financial statement prepared as per Indian Accounting Standard (Ind-AS) for the financial year ended on March 31, 2026 which forms part of Annual Report for the financial year 2025-26, available at the following weblink: https://indiqube.com/investor/financials/
8	Employee wise details (name of employee, designation, number of options granted during the year, exercise price) of options granted to -		Nil, no options were granted during the financial year ended March 31, 2026
	a	senior managerial personnel as defined under Regulation 16(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;	
	b	any other employee who receives a grant in any one year of option amounting to 5% or more of option granted during that year; and	
	c	identified employees who were granted option, during any one year, equal to or exceeding 1% of the issued capital (excluding outstanding warrants and conversions) of the company at the time of grant.	
9	A description of the method and significant assumptions used during the year to estimate the fair value of options including the following information:		Members may refer to note No. 34 of the financial statement prepared as per Indian Accounting Standard (Ind-AS) for the financial year ended on March 31, 2026 which forms part of Annual Report for the financial year 2025-26, available at the following weblink: https://indiqube.com/investor/financials/
	a	the weighted-average values of share price, exercise price, expected volatility, expected option life, expected dividends, the risk-free interest rate and any other inputs to the model	
	b	the method used and the assumptions made to incorporate the effects of expected early exercise;	
	c	how expected volatility was determined, including an explanation of the extent to which expected volatility was based on historical volatility; and	
	d	whether and how any other features of the options granted were incorporated into the measurement of fair value, such as a market condition.	